Objective: Missense mutations in HIV-1 reverse transcriptase are frequently selected in response to therapy; we examined whether silent mutations were also selected for by HIV therapy.
Introduction
The HIV-1 reverse transcriptase facilitates the conversion of the viral single stranded RNA genome into double stranded DNA. Reverse transcriptase is a multifunctional enzyme and exhibits RNA-dependent DNA polymerase, DNA-dependent DNA polymerase, and ribonuclease H activities. Because of its essential role in HIV-1 replication, reverse transcriptase is a primary target for drug development [1] . Currently, two therapeutic classes of reverse transcriptase inhibitors (RTIs) -the nucleoside or nucleotide RTIs (NRTIs) and nonnucleoside RTIs (NNRTIs) [1] -are routinely used to treat HIV infection. However, the long-term efficacy of combination therapies that contain RTIs is limited by the selection of missense mutations, which confer amino acid substitutions in the reverse transcriptase that lead to HIV drug resistance [2] .
Amino acid substitutions in reverse transcriptase associated with NRTI and NNRTI resistance have been generally well defined and well characterized [3] . For example, NRTI-associated resistance mutations can be broadly categorized into two groups, depending on their phenotypic mechanism of resistance. The K65R, K70E, L74V, Q151M, and M184V mutations primarily increase the selectivity of reverse transcriptase for the incorporation of a natural deoxynucleotide triphosphate (dNTP) substrate over an NRTI-triphosphate [4] . By contrast, the mutations M41L, D67N, K70R, L210W, T215F/Y, and K219Q/E -typically referred to as thymidine analogue mutations (TAMs) -augment the ability of HIV-1 reverse transcriptase to excise the chain-terminating NRTImonophosphate from a prematurely terminated DNA chain [4] .
In contrast to missense mutations, silent mutations do not result in a change to the primary amino acid sequence of the enzyme. As a result, they are typically treated as evolutionarily neutral and are largely overlooked in HIV genotypic analyses. However, in some cases, silent mutations have been shown to alter protein translational kinetics, which in turn may affect splicing, or transcriptional control, ultimately affecting subsequent protein expression and activity [5, 6] . In this study, we investigated whether HIV-1 coselects for silent mutations in the HIV-1 reverse transcriptase gene under selective antiviral drug pressure.
Methods

Prevalence of mutations
The prevalence of all reverse transcriptase mutations with respect to a wild-type reference sequence (HIV HXB2; GenBank Accession #K03455) was determined in 20 017 archived plasma samples. Using a list of key drug mutations modified from the International AIDS Society, USA (IAS) [3] , we examined the prevalence of all mutations in samples stratified as either 'wild-type' (i.e. not having IAS 'key resistance mutations') or 'nonwildtype' (Fig. 1a and b , respectively). The mutations we examined by drug category were lamivudine (184I/V); any other nucleoside reverse transcriptase (NRTIs) (41L, 62V, 65R, 67N, 69D, or insertion, 70R, 74V, 75I, 151M, 210W, 215F/Y, or 219E/Q); any reverse transcriptase NNRTIs (100I, 103N, 106A/M, 108I, 181C/I, 188C/  H/L, 190A/S, P225H, M230L, or 236L); and any  protease inhibitors (30N, 33F , 46I/L, 48V, 50L/V, 54V/ L/M, 82A/F/S/T, 84V, or 90M). To show amino acid changes, we compared the difference in the prevalence of amino acid substitutions between 'wild-type' and 'nonwild-type' samples (b minus a) ( Fig. 1c ).
Clinical correlates of silent mutation selection
In order to establish the clinical correlates of these silent mutations, data for silent AAG (or mixtures) at reverse transcriptase codons 65 and/or 66 were pooled from all individuals with available genotypes in members of the previously well characterized HOMER ('HAART Observational Medical Evaluation and Research') cohort [7, 8] infected with subtype B HIV-1 (N ¼ 2542). Patients were at least 18 years of age and antiretroviral therapynaive when they started HAART and initiated treatment between 1 August 1996 and 30 November 2005. All participants had a CD4 cell count and plasma viral load (pVL) measurement within 6 months of their first antiretroviral start date. Study data from eligible participants were extracted from the British Columbia Centre for Excellence in HIV/AIDS' monitoring and evaluation system. Associations between baseline characteristics (sex, AIDS diagnosis, history of injection drug use, year of first therapy, adherence strata, CD4 cell count, and pVL) and exposure to specific NRTI drugs during therapy (lamivudine, abacavir, zidovudine, stavudine, zalcitabine, didanosine, and tenofovir) were tested using the x 2 method, with Bonferroni corrections made for multiple comparisons. We also wished to assess the clinical impact of K65/66K silent mutations on pVL during therapy. Significance of the differences in pre and post K65/66K pVL was determined using the Wilcoxon signed-rank test.
Steady-state kinetic assays D67N/K70R/T215F/K219Q (TAM67) and TAM67/ K65R HIV-1 reverse transcriptase were generated by site-directed mutagenesis of wild-type HIV-1 LAI reverse transcriptase [9, 10] . Recombinant reverse transcriptases were overexpressed and purified to homogeneity as described previously [11, 12] . Reverse transcriptase concentration was determined spectrophotometrically at 280 nm, using an extinction coefficient (e280) of 260 450 M À1 cm À1 and the active site concentration was calculated from presteady-state burst experiments [13] . All experiments were performed using corrective active site concentrations.
DNA and RNA oligomers were synthesized by Integrated DNA technologies (Coralville, Iowa, USA). The RNA templates spanned codons 62-77 of the HIV-1 reverse transcriptase gene and included different combinations of mutations at codons 65 (AAA, AGA, AAG), 66 (AAA, AAG), 67 (GAC, AAC), and 70 (AAA, AGA). A complementary 20 nucleotide DNA primer (5 0 -TGAAATCTCTAATTTTCTCC-3 0 ) was used to prime reverse transcriptase-mediated DNA synthesis reactions. The primer was 5 0 -radiolabeled with [g-32 P]-ATP (GE Healthcare, Piscataway, New Jersey, USA) and annealed to the respective RNA templates, as described previously [9, 10] .
Steady-state DNA polymerization assays were carried out in 50 mmol/l Tris-HCl pH 7.8 (378C), 50 mmol/l KCl, 10 mmol/l MgCl 2 containing 200 nmol/l of T/P, and 5 mmol/l dNTP. Reactions were initiated by the addition of 50 nmol/l wild-type or mutant (TAM67 or TAM67/ K65R) HIV-1 reverse transcriptase. Aliquots were removed at designated times (1, 2.5, 3.5, 5.5, 7.5, 10, and 20 min) and mixed with an equal volume of sample loading buffer [98% deionized formamide, 10 mmol/l ethylenediaminetetraacetic acid (EDTA), and 1 mg/ml each of bromophenol blue and xylene cyanol]. Samples were denatured at 858C for 5 min, products were separated on a 7 mol/l urea-14% polyacrylamide gel, and detected using a Bio-Rad GS525 Molecular Imager (Bio-Rad Laboratories, Hercules, California, USA).
RNA structural determinations
Preliminary modeling of the minimum free energy secondary structure of isolated HIV-1 reverse transcriptase RNA sequences, spanning codons 55-75, was conducted using the Vienna RNA Secondary Structure Package (http://www.tbi.univie.ac.at/RNA/). Input sequences included wild-type and several variants containing nonsynonymous mutations at codons 65, 67, and 70, as well as silent mutations at codons 65 and 66.
Results
Silent mutations in HIV-1 reverse transcriptase are associated with treatment experience Figure 1a shows the prevalence of all mutations with respect to HXB2 at the individual reverse transcriptase codons for samples that were classified as 'wild-type', whereas Fig. 1b shows mutation prevalences for 'nonwildtype'samples. The difference in prevalence between 'wildtype' and 'nonwild-type' samples for mutations that conferred amino acid changes is shown in Fig. 1c . The prevalence of silent mutations, relative to HXB2 clade B consensus ( Fig. 1d ), revealed that only two silent mutations at codons K65 and/or K66 in reverse transcriptase were strongly associated with treatment experience and both were highly significant after correction for multiple comparisons. The prevalence of silent mutations at codons K65 and/or K66 in treatment-experienced patients increased by 3.0 and 9.8%, respectively, relative to the naive population. This degree of selection actually exceeds the degree of selection of most of the known IAS drug resistance mutations. Silent AAA to AAG (or mixtures) mutations at reverse transcriptase codons 65 and/or 66 were observed in 812 samples from 351 patients and 2129 samples from 829 patients, respectively. Similar selection of silent mutations at codons 65 and 66 was observed in the Stanford HIV Drug Resistance Database (http:// hivdb. stanford.edu; data not shown). We also investigated the prevalence of all mutations with respect to HXB2 at individual reverse transcriptase codons from first available pretherapy genotypes, as well as the prevalence of mutations at the last available on-therapy genotypes, to ensure that only a single post-treatment sample per patient was examined. The results were similar, showing an increase in the prevalence of silent mutations at codons 65K and/or 66K between last available on-therapy and first available pretherapy sample (data not shown).
Thymidine analogue mutations are strongly associated with silent mutations Pooled data from available HIV-1 subtype B reverse transcriptase sequences in the British Columbia Centre for Excellence in HIV/AIDS database were used to identify the resistance mutations that are most commonly associated with the presence of 65K and/or 66K silent mutations (Table 1 ). In subtype B samples, there was a very strong correlation between the silent mutations and TAMs. In particular, at position 67 of the reverse transcriptase, 7% of wild-type D67 samples had the 65K and/or 66K silent mutations, compared with over 80% of samples with the D67N substitution (P << 0.001). These associations were confirmed in two independent resistance datasets (the Stanford HIV Drug Resistance Database and Virco; data not shown).
Clinical correlates of silent mutation selection Although the TAMs are considered to arise on exposure to the thymidine analogues (stavudine or, particularly, zidovudine), exposure to zidovudine was not associated with the selection of the silent mutations. However, exposure to the other NRTIs (abacavir, stavudine, didanosine, or tenofovir) during therapy was associated with the selection of silent mutations at position 65 and 66 (Table 2 ) in a dose-dependent manner [analysis of variance (ANOVA) F-test P ¼ 0.01] (Fig. 2) . Note that the amino acid substitution K65R has been implicated in resistance to many of these agents and is itself antagonistic to TAMs. The mean pVL for individuals before the first positive test for K65/66K silent mutations was 3.89 log 10 and 4.01 log 10 at the first positive test (Wilcoxon signedrank test P ¼ 0.0064). Although statistically significant, this is not likely to be a clinically significant difference. Male sex, no history of injection drug use, and low baseline CD4 cell count were each associated with the presence of the K65/66K mutations (Table 2) . However, these associations may not be causal, but could be correlated with silent mutations because of the association of these variables with the development of extensive resistance in general.
RNA structural determinations
Preliminary investigations modeling the secondary structure of isolated wild-type HIV-1 RNA templates and several templates with various combinations of codon changes at positions 65, 66, 67, and 70 showed most of the silent changes occurred in a loop of the secondary RNA structure, and therefore, it would not be expected to result in significant structural changes between secondary structures.
Silent mutations compensate for replication block of D67N/K70R
To address a possible mechanism by which the silent mutations at codons 65 and 66 in the HIV-1 reverse transcriptase gene might affect virus replication, we assessed the ability of recombinant HIV-1 reverse transcriptase that was wild-type or contained the TAMs D67N, K70R, T215F, and K219Q (TAM67 RT) to copy RNA templates that spanned codons 62-77 in reverse transcriptase and included different combinations of mutations at codons 65 (AAA, AGA, AAG), 66 (AAA, AAG), 67 (GAC, AAC), and 70 (AAA, AGA). Under steady-state kinetic conditions, both the wild-type and TAM67 reverse transcriptases exhibited a stronger tendency to pause/dissociate at codons 65 and 66 on RNA templates containing the D67N/K70R mutations (template RH1) in comparison to the wild-type sequence (Fig. 3a, c) . However, when the K65 or K66 AAA to AAG mutations were added to the background of the D67N and K70R mutational changes (templates RH3 and RH2, respectively), these pausing and/or dissociation events were largely alleviated (Fig. 3a, c) . Interestingly, for both reverse transcriptase enzymes, the introduction of the K65R mutation (AAA to AGA) into the RNA Fig. 2 . Percentage of patients with a 65K and/or 66K silent mutation as a function of the number of nucleoside or nucleotide reverse transcriptase inhibitors exposed to during treatment (abacavir, stavudine, didanosine, or tenofovir). The total number of patients for each exposure, including those without K65/66K mutations, is shown below each grouping. Analysis of variance (ANOVA) F-test; P ¼ 0.01. NRTI, nucleoside or nucleotide reverse transcriptase inhibitor. template (template RH4) also alleviated the replication block resulting from the 67 and 70 mutational changes (Fig. 3b, c) . Together, these results suggest that mutations at codons 65 and 66 in the RNA template compensate for a replication block triggered by the D67N/K70R mutations.
As described above, silent mutations at codons 65 and 66 in the reverse transcriptase gene are highly associated with TAMs, and in particular D67N. However, antagonism between missense mutations at K65 (e.g. K65R) and TAMs has previously been reported at the genomic, viral, and enzyme level in subtype B reverse transcriptase, indicating that the virus cannot readily accommodate both TAMs and K65R in reverse transcriptase [10, 14, 15] . Accordingly, we were also interested in the ability of reverse transcriptase enzymes containing TAMs and K65R (i.e. TAM67/K65R RT) to copy RNA templates that contained codon changes at positions 65, 66, 67, and 70 (Fig. 3d ). In comparison with wild-type and TAM67 HIV-1 reverse transcriptase, the TAM67/K65R enzyme exhibited a decreased tendency to pause at codons 66 and 67 on the RH1 template. Furthermore, the silent AAA to AAG change at codon 65 in combination with the D67N and K70R (template RH3) had minimal effect of the overall polymerization pattern of the enzyme. However, on templates that included the K65R mutation (RH4), TAM67/K65R reverse transcriptase exhibited a very strong tendency to pause at codons 65, 66, and 67. Interestingly, the introduction of silent mutation into templates with 67N/70R/K65R mutations does not alleviate the block experienced by reverse transcriptase with K65RþTAMs ( Fig. 3d; RH5 ). Furthermore, the addition of the K66 AAA to AAG silent mutation to this template (RH5) did not compensate for this increased pausing. In fact, the enzyme exhibited a very distributive mode of polymerization; by contrast, both the wild-type and TAM67 reverse transcriptase could replicate very efficiently on this template (data not shown). Taken together, these data show that antagonism between reverse transcriptase codon 65 and TAMs may also extend to the RNA level. 
Discussion
Our results reveal the surprising finding that silent mutations at K65 and/or K66 of the HIV-1 reverse transcriptase are strongly selected for during antiretroviral therapy. These silent mutations are particularly observed in association with mutations at HIV-1 reverse transcriptase codon 67. Selection was associated with exposure to the NRTIs abacavir, didanosine, stavudine, and/or tenofovir. Enzymatic data suggest that the silent mutations may play a role in the efficiency of viral DNA synthesis and also highlight a previously unobserved aspect of antagonism between K65 mutations and TAMs at the level of reverse transcription. Subsequently, there have been two independent follow-up studies that showed similar results [16, 17] .
Other studies have focused on the predisposition of virus with silent mutations in the evolution of HIV drug resistance, particularly with respect to non-B subtypes, but none have tied the actual evolution of silent mutations to drug exposure. Loemba et al. [18] identified several silent mutations at codons 62, 65, 106, 138, and 161 associated with antiretroviral resistance in subtype C. Additionally, Turner et al. [19] described a G48G silent mutation within the protease region of subtype C subtypes, as well as a T215T silent mutation present in subtype A and A/E subtypes. However, to our knowledge no silent mutations have been demonstrated to be selected for by antiretroviral drug pressure, and indeed, this may represent the first observation of the selection of a synonymous mutation in response to a known selective pressure occurring in a natural setting.
Using data from the Los Alamos HIV sequence database, we noted that consensus codons 64, 65, and 66 in wildtype subtype C HIV-1 differ from other subtypes in this region. Whereas subtype C has AAA, AAG, and AAG at codons 64, 65, and 66, respectively, subtypes B-F have AAG, AAA, and AAA at codons 64, 65, and 66, respectively. There have been recent suggestions that silent mutations in the subtype C reverse transcriptase gene were responsible for the rapid selection of the K65R mutation [20, 21] . Another unique feature of subtype C virus is that the K65R mutation that develops in subtype C is AGG, whereas in subtype B it is almost exclusively AGA (data not shown). Although our results are analogous, they are likely not directly relevant to subtype C HIV-1.
An important limitation of our preliminary investigations of secondary RNA structure was that they were conducted on isolated RNA sequences and we cannot make any inferences about the effects on a RNA sequence that is undergoing reverse transcription. In addition, we have only examined the effect of the silent mutations on RNA-dependent DNA polymerization. As HIV-1 reverse transcriptase is a multifunctional enzyme, it is also possible that silent changes in the RNA template affect the efficiency of the DNA-dependent DNA polymerization and/or ribonuclease H activity of HIV-1 reverse transcriptase, but these were not investigated.
The data show that mutations at codons 65 and/or 66 are coselected with TAMs, and therefore, provide an interesting and potentially clinically relevant example of situations in which silent amino acid changes may not be evolutionarily neutral. These data also provide the first evidence for an RNA-level mechanism of direct relevance to drug resistance. Further investigations should be conducted to more accurately identify the mechanism by which these silent mutations are effecting viral evolution, along with other studies to try and identify any further examples of silent mutation selection in response to therapy across the HIV genome.
